<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002347</url>
  </required_header>
  <id_info>
    <org_study_id>229C</org_study_id>
    <secondary_id>ICC 001</secondary_id>
    <nct_id>NCT00002347</nct_id>
  </id_info>
  <brief_title>The Safety and Effectiveness of Retrovir Plus HIVID Combined With Either Nevirapine or Invirase in the Treatment of HIV Infection</brief_title>
  <official_title>A Master Protocol to Evaluate the Safety and Efficacy of Multi-Drug Combination Antiretroviral Therapy for the Treatment of HIV Infection: Retrovir/HIVID/Nevirapine and Retrovir/HIVID/Invirase</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Parexel</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NIH AIDS Clinical Trials Information Service</source>
  <brief_summary>
    <textblock>
      To evaluate the tolerance and immunologic and virologic effects of multidrug combinations of&#xD;
      antiretrovirals in patients with HIV infection. Specifically, to evaluate&#xD;
      zidovudine/zalcitabine ( AZT / ddC ) alone or in combination with either nevirapine or&#xD;
      saquinavir ( Ro 31-8959 ).&#xD;
&#xD;
      Administration of three-drug combinations for treatment of HIV infection is preferred over&#xD;
      monotherapy or duotherapy. A system has been designed to rapidly evaluate current multidrug&#xD;
      combinations of antiretrovirals and allow the addition of new agents as they become&#xD;
      available.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Administration of three-drug combinations for treatment of HIV infection is preferred over&#xD;
      monotherapy or duotherapy. A system has been designed to rapidly evaluate current multidrug&#xD;
      combinations of antiretrovirals and allow the addition of new agents as they become&#xD;
      available.&#xD;
&#xD;
      Patients are randomized to receive AZT/ddC either alone or in combination with nevirapine or&#xD;
      Ro 31-8959 for a minimum of 48 weeks. Patients are followed at weeks 2 and 4 and every 4&#xD;
      weeks thereafter.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <enrollment>225</enrollment>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saquinavir</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nevirapine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zidovudine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zalcitabine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Encouraged:&#xD;
&#xD;
          -  PCP chemoprophylaxis for patients whose CD4 count falls below 200 cells/mm3 or who&#xD;
             develop PCP on study.&#xD;
&#xD;
        Allowed:&#xD;
&#xD;
          -  Secondary prophylaxis with nonexperimental agents in patients who develop TB,&#xD;
             Mycobacterium avium-intracellulare, toxoplasmosis, histoplasmosis, cryptococcosis,&#xD;
             disseminated candidiasis, or cytomegalovirus infection.&#xD;
&#xD;
          -  Acyclovir for 21 days or less for acute treatment.&#xD;
&#xD;
          -  Recombinant erythropoietin and G-CSF for grade 3 or worse anemia and neutropenia,&#xD;
             respectively.&#xD;
&#xD;
        Patients must have:&#xD;
&#xD;
          -  HIV infection.&#xD;
&#xD;
          -  CD4 count 200 - 500 cells/mm3.&#xD;
&#xD;
          -  No prior antiretroviral therapy.&#xD;
&#xD;
          -  Life expectancy of at least 48 weeks.&#xD;
&#xD;
          -  Consent of parent or guardian if less than 18 years of age.&#xD;
&#xD;
        NOTE:&#xD;
&#xD;
          -  Participating centers are encouraged to enroll female patients.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
        Co-existing Condition:&#xD;
&#xD;
        Patients with the following symptoms or conditions are excluded:&#xD;
&#xD;
          -  Any grade 3 or greater toxicity.&#xD;
&#xD;
          -  Symptoms of peripheral neuropathy.&#xD;
&#xD;
          -  Malabsorption or severe chronic diarrhea.&#xD;
&#xD;
          -  Inability to eat at least one meal daily because of chronic nausea, emesis, or&#xD;
             abdominal or esophageal discomfort.&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Excluded during the first 28 days of nevirapine administration:&#xD;
&#xD;
          -  Augmentin and other antibiotics containing clavulanic acid.&#xD;
&#xD;
        Excluded at any time:&#xD;
&#xD;
          -  Dicumarol, warfarin, and other anticoagulant medications.&#xD;
&#xD;
          -  Tolbutamide.&#xD;
&#xD;
          -  Cimetidine.&#xD;
&#xD;
          -  Erythromycin.&#xD;
&#xD;
        Patients with the following prior conditions are excluded:&#xD;
&#xD;
          -  History of acute or chronic pancreatitis.&#xD;
&#xD;
          -  History of grade 2 or worse peripheral neuropathy from any cause.&#xD;
&#xD;
        Prior Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Any prior antiretroviral therapy.&#xD;
&#xD;
        Excluded within 4 weeks prior to study entry:&#xD;
&#xD;
          -  Immunomodulating agents such as systemic corticosteroids, IL-2, alpha-interferon,&#xD;
             beta-interferon, or gamma-interferon.&#xD;
&#xD;
          -  Immunotherapeutic vaccines.&#xD;
&#xD;
          -  Cytotoxic chemotherapy.&#xD;
&#xD;
          -  Erythromycin.&#xD;
&#xD;
          -  Dicumarol, Coumadin / warfarin, and other anticoagulant medications.&#xD;
&#xD;
          -  Phenobarbital.&#xD;
&#xD;
          -  Amoxicillin / clavulanate.&#xD;
&#xD;
          -  Ticarcillin / clavulanate.&#xD;
&#xD;
          -  Tolbutamide.&#xD;
&#xD;
          -  Erythromycin.&#xD;
&#xD;
          -  Cimetidine.&#xD;
&#xD;
        Prior Treatment:&#xD;
&#xD;
        Excluded within 4 weeks prior to study entry:&#xD;
&#xD;
          -  Non-local radiation therapy. Current alcohol or illicit drug use that would interfere&#xD;
             with ability to comply with study requirements.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>13 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>PAREXEL Intl Corp / InterCo Collaboration Ctr</name>
      <address>
        <city>Waltham</city>
        <state>Massachusetts</state>
        <zip>02154</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Thompson M, Myers M, Salgo M, Rousseau F, Odorisio M, Warburg M. A master protocol to evaluate the safety and efficacy of multidrug combination antiretroviral therapy with zidovudine and zalcitabine with or without saquinavir or nevirapine for the treatment of HIV infection. Conf Retroviruses Opportunistic Infect. 1997 Jan 22-26;4th:109 (abstract no 242)</citation>
  </reference>
  <verification_date>June 1995</verification_date>
  <study_first_submitted>November 2, 1999</study_first_submitted>
  <study_first_submitted_qc>August 30, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2001</study_first_posted>
  <last_update_submitted>June 23, 2005</last_update_submitted>
  <last_update_submitted_qc>June 23, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2005</last_update_posted>
  <keyword>Zalcitabine</keyword>
  <keyword>Drug Therapy, Combination</keyword>
  <keyword>Acquired Immunodeficiency Syndrome</keyword>
  <keyword>AIDS-Related Complex</keyword>
  <keyword>Zidovudine</keyword>
  <keyword>Nevirapine</keyword>
  <keyword>Saquinavir</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Zidovudine</mesh_term>
    <mesh_term>Nevirapine</mesh_term>
    <mesh_term>Zalcitabine</mesh_term>
    <mesh_term>Saquinavir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

